Author： Högberg M. Morrison I.
Publisher： Informa Healthcare
ISSN： 1354-3776
Source： Expert Opinion on Therapeutic Patents, Vol.10, Iss.8, 2000-08, pp. : 1189-1199
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Two classes of anti-HIV drugs are currently marketed which target the HIV-1 reverse transcriptase (RT). The first explored class was the nucleoside RT inhibitors (NRTIs), such as AZT, ddI, ddC, 3TC, D4T and abacavir, whereas the more recently launched class are the non-nucleoside RT inhibitors (NNRTI) currently comprising nevirapine (Viramune™, Boehringer Ingelheim), delavirdine (Rescriptor™, Pharmacia and Upjohn) and efavirenz (Sustiva™, Dupont Pharmaceuticals). The NNRTI class is in rapid development to find more clinically useful inhibitors, especially against inhibitor-induced mutant RT enzymes. This article covers development in the area of HIV-1 NNRTI from 1997 through early 2000.
Related content
Non-nucleoside inhibitors of HIV-1 reverse transcriptase
Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 8, 1998-08 ,pp. :
Access to resources
Recommend
